During Men’s Health Month each June, CyberKnife Center of Chicago joins the movement to help heighten awareness of preventable health problems and encourage early detection and treatment of disease among men.
Through an ever-expanding base of clinical research and studies, we continue to gain valuable knowledge and understanding of diseases that affect many men and move one step closer in the fight against cancer.
A recent study confirmed the efficacy and safety of CyberKnife® treatment for localized prostate cancer. As part of the study, 32 patients were treated for early stage prostate cancer with CyberKnife stereotactic body radiation therapy (SBRT) between October 2012 and January 2014. At the last follow up visit, all patients were still alive and 29 remained free of disease. The results of the study show that CyberKnife can serve as a viable treatment option for early stage prostate cancer.
At CyberKnife Center of Chicago, we treat prostate cancer with SBRT using highly advanced CyberKnife technology. To learn more about our approach, read about our treatment process and take a look at these research findings, which support SBRT as an appropriate treatment option for prostate cancer.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.